A Critical Function for B-Raf at Multiple Stages of Myelopoiesis

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2005 Mar 24

PMID 15784729

Citations 17

Authors

Tamihiro Kamata

Jing Kang

Tzong-Hae Lee

Leszek Wojnowski

Catrin A Pritchard

Andrew D Leavitt

Affiliations

Soon will be listed here.

Abstract

Raf kinases play an integral role in the classic mitogen-activated protein (MAP) kinase (Raf/MEK/extracellular signal-related kinase [ERK]) intracellular signaling cascade, but their role in specific developmental processes is largely unknown. Using a genetic approach, we have identified a role for B-Raf during hematopoietic progenitor cell development and during megakaryocytopoiesis. Fetal liver and in vitro embryonic stem (ES) cell-derived myeloid progenitor development is quantitatively impaired in the absence of B-Raf. Biochemical data suggest that this phenotype is due to the loss of a normally occurring rise in B-Raf expression and associated ERK1/2 activation during hematopoietic progenitor cell formation. However, the presence of B-raf-/- ES cell-derived myeloid progenitors in the bone marrow of adult chimeric mice indicates the lack of an obligate cell-autonomous requirement for B-Raf in myeloid progenitor development. The lack of B-Raf also impairs megakaryocytopoiesis. Thrombopoietin (Tpo)-induced in vitro expansion of ES cell-derived megakaryocyte-lineage cells fails to occur in the absence of B-Raf. Moreover, this quantitative in vitro defect in megakaryocyte-lineage expansion is mirrored by chimeric mice data that show reduced B-raf-/- genotype contribution in megakaryocytes relative to its contribution in myeloid progenitors. Together, these data suggest that B-Raf plays a cell-autonomous role in megakaryocytopoiesis and a permissive role in myeloid progenitor development.

Citing Articles

Mutations in Patients with Myeloid Neoplasms: A Cancer Center Multigene Next-Generation Sequencing Analysis Experience.

Fei F, Caporale C, Chang L, Fortini B, Ali H, Bell D Int J Mol Sci. 2024; 25(10).

PMID: 38791222 PMC: 11121641. DOI: 10.3390/ijms25105183.

DMM Outstanding Paper Prize 2022 winners: Tamihiro Kamata, Jennifer K. Sargent and Mark A. Warner.

Hackett R Dis Model Mech. 2023; 16(4).

PMID: 37144683 PMC: 10184667. DOI: 10.1242/dmm.050268.

and Functional Redundancy in Erythropoiesis.

Beuret L, Fortier-Beaulieu S, Rondeau V, Roy S, Houde N, Balabanian K Front Cell Dev Biol. 2021; 9:639022.

PMID: 34386488 PMC: 8353236. DOI: 10.3389/fcell.2021.639022.

BRAFV 600E or mutant MAP2K1 human CD34+ cells establish Langerhans cell-like histiocytosis in immune-deficient mice.

Rafiei A, Wilk C, Helbling P, Myburgh R, Saito Y, Haralambieva E Blood Adv. 2020; 4(19):4912-4917.

PMID: 33035332 PMC: 7556147. DOI: 10.1182/bloodadvances.2020001926.

Clonal hematopoietic mutations linked to platelet traits and the risk of thrombosis or bleeding.

Veninga A, de Simone I, Heemskerk J, Ten Cate H, van der Meijden P Haematologica. 2020; 105(8):2020-2031.

PMID: 32554558 PMC: 7395290. DOI: 10.3324/haematol.2019.235994.

References

Kamata T, Pritchard C, Leavitt A . Raf-1 is not required for megakaryocytopoiesis or TPO-induced ERK phosphorylation. Blood. 2003; 103(7):2568-70. DOI: 10.1182/blood-2003-06-1803. View

Goncalves F, Lacout C, Villeval J, Wendling F, Vainchenker W, Dumenil D . Thrombopoietin does not induce lineage-restricted commitment of Mpl-R expressing pluripotent progenitors but permits their complete erythroid and megakaryocytic differentiation. Blood. 1997; 89(10):3544-53. View

Hirashima M, Bernstein A, Stanford W, Rossant J . Gene-trap expression screening to identify endothelial-specific genes. Blood. 2004; 104(3):711-8. DOI: 10.1182/blood-2004-01-0254. View

Ahmad T, Eisen T . Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res. 2004; 10(18 Pt 2):6388S-92S. DOI: 10.1158/1078-0432.CCR-040028. View

Wilhelm S, Carter C, Tang L, Wilkie D, McNabola A, Rong H . BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004; 64(19):7099-109. DOI: 10.1158/0008-5472.CAN-04-1443. View

Radich J, Kopecky K, Willman C, Weick J, Head D, Appelbaum F . N-ras mutations in adult de novo acute myelogenous leukemia: prevalence and clinical significance. Blood. 1990; 76(4):801-7. View

Kyriakis J, App H, Zhang X, Banerjee P, Brautigan D, Rapp U . Raf-1 activates MAP kinase-kinase. Nature. 1992; 358(6385):417-21. DOI: 10.1038/358417a0. View

Dent P, Haser W, Haystead T, Vincent L, Roberts T, Sturgill T . Activation of mitogen-activated protein kinase kinase by v-Raf in NIH 3T3 cells and in vitro. Science. 1992; 257(5075):1404-7. DOI: 10.1126/science.1326789. View

Howe L, Leevers S, Gomez N, Nakielny S, Cohen P, Marshall C . Activation of the MAP kinase pathway by the protein kinase raf. Cell. 1992; 71(2):335-42. DOI: 10.1016/0092-8674(92)90361-f. View

10.

Ogawa M . Differentiation and proliferation of hematopoietic stem cells. Blood. 1993; 81(11):2844-53. View

11.

Murphy E, Lee T, Chafets D, Nass C, Wang B, Loughlin K . Higher human T lymphotropic virus (HTLV) provirus load is associated with HTLV-I versus HTLV-II, with HTLV-II subtype A versus B, and with male sex and a history of blood transfusion. J Infect Dis. 2004; 190(3):504-10. DOI: 10.1086/422398. View

12.

Kimura S, Roberts A, Metcalf D, Alexander W . Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin. Proc Natl Acad Sci U S A. 1998; 95(3):1195-200. PMC: 18717. DOI: 10.1073/pnas.95.3.1195. View

13.

Kerkhoff E, Rapp U . Cell cycle targets of Ras/Raf signalling. Oncogene. 1998; 17(11 Reviews):1457-62. DOI: 10.1038/sj.onc.1202185. View

14.

Drachman J, Rojnuckarin P, Kaushansky K . Thrombopoietin signal transduction: studies from cell lines and primary cells. Methods. 1999; 17(3):238-49. DOI: 10.1006/meth.1998.0734. View

15.

Kaushansky K . Thrombopoietin and hematopoietic stem cell development. Ann N Y Acad Sci. 1999; 872:314-9. DOI: 10.1111/j.1749-6632.1999.tb08475.x. View

16.

Rojnuckarin P, Drachman J, Kaushansky K . Thrombopoietin-induced activation of the mitogen-activated protein kinase (MAPK) pathway in normal megakaryocytes: role in endomitosis. Blood. 1999; 94(4):1273-82. View

17.

Wojnowski L, Zimmer A, Beck T, Hahn H, Bernal R, Rapp U . Endothelial apoptosis in Braf-deficient mice. Nat Genet. 1997; 16(3):293-7. DOI: 10.1038/ng0797-293. View

18.

Shiraga M, Ritchie A, Aidoudi S, Baron V, Wilcox D, White G . Primary megakaryocytes reveal a role for transcription factor NF-E2 in integrin alpha IIb beta 3 signaling. J Cell Biol. 1999; 147(7):1419-30. PMC: 2174239. DOI: 10.1083/jcb.147.7.1419. View

19.

Ogawa M . Stochastic model revisited. Int J Hematol. 2000; 69(1):2-5. View

20.

Wojnowski L, Stancato L, Larner A, Rapp U, Zimmer A . Overlapping and specific functions of Braf and Craf-1 proto-oncogenes during mouse embryogenesis. Mech Dev. 2000; 91(1-2):97-104. DOI: 10.1016/s0925-4773(99)00276-2. View